Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04833114
Title Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) (Pola-R-ICE)
Acronym Pola-R-ICE
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors GWT-TUD GmbH
Age Groups: senior | adult
Covered Countries GBR | ESP | DEU | AUT

No variant requirements are available.